Drug intelligence / Profile preview

CSR02-Fab-TF

Development stage: Phase 1
Lead developer: Koo Foundation Sun Yat-sen Cancer Center
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intra-arterial

Overview

CSR02-Fab-TF is an intra-arterial therapy designed to target blood vessels feeding hepatocellular carcinoma tumors while sparing normal liver tissue. It consists of a Fab fragment from an antibody (CSR02) that recognizes PLVAP (Plasmalemma Vesicle-Associated Protein), combined with tissue factor, a normal human protein that promotes blood clotting. This design allows it to selectively target and block tumor blood vessels, depriving the tumor of its blood supply and leading to tumor death.

Targets

PLVAP (Plasmalemma vesicle-associated protein)

Beyond the preview

Go deeper on CSR02-Fab-TF.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CSR02-Fab-TF.

Explore the full profile